Thyroid hormone
Levothyroxine (T4)
The Synthroid label lists levothyroxine's half-life as 6 to 7 days in euthyroid patients and 9 to 10 days in hypothyroidism; the app lists 168 hours, 7 days.1
Levothyroxine (T4) after one dose: 50% at ~7 days, 25% at 14 days, 12.5% at 21 days.
Drawn from the half-life in the app's model, ~7 days. The model's figures
- Compound
- Levothyroxine (T4)
- Symbol
- T4
- Family
- Metabolic and mitochondrial peptides
- Parts
- 14
- References
- 11
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Levothyroxine (T4) is the thyroid hormone L-thyroxine, sold as a tablet under brand names that include Synthroid and Levoxyl, and the app files it under the metabolic category with the sub-category Thyroid Hormone.1,2 The Synthroid label states that "Synthetic T4 is chemically identical to that produced in the human thyroid gland".1 The Synthroid label lists two uses in adult and pediatric patients, including neonates: replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism, and, as an adjunct to surgery and radioiodine therapy, pituitary thyrotropin (TSH) suppression in thyrotropin-dependent well-differentiated thyroid cancer.1 The label's Limitations of Use state that it is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients, or for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.1 Both US labels carry a prescription-only marking and give 2002 (Synthroid, AbbVie) and 2001 (Levoxyl, Pfizer) as the initial US approval year.1,2 The Synthroid label carries a boxed warning headed "WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS".1 The boxed text adds that doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity.1 The highlights section of the label adds that larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.1 The app grades the evidence for levothyroxine as strong; the sources cited here are two US labels, a guideline, one randomised trial and a pair of parallel randomised trials with their registry entries, one cohort study, two absorption studies in eight and ten healthy volunteers, and the WADA Prohibited List.
How it works
Sources in this part
The Synthroid label states that thyroid hormones "exert their physiologic actions through control of DNA transcription and protein synthesis".1 It adds that the actions are produced predominantly by T3, "the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues".1 For oral levothyroxine the label states that it "exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present".1 The label states that circulating thyroid hormones are "greater than 99% bound to plasma proteins".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~7 days
- Bioavailability
- 70%
- Typical dose
- 25–200 mcg/day
- Route
- Oral
- Time to peak
- ~3 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~7 days (168 h) | Table 10 of the Synthroid label lists 6 to 7 days in euthyroid patients, with a footnote of 3 to 4 days in hyperthyroidism and 9 to 10 days in hypothyroidism; the Levoxyl label carries the same footnote1,2 |
| Bioavailability | 70% (oral) | Synthroid label: absorption of orally administered T4 from the gastrointestinal tract "ranges from 40% to 80%", and tablets are approximately 93% bioavailable relative to an equal nominal dose of oral levothyroxine sodium solution; Levoxyl label: the same 40% to 80% range, with tablets approximately 95% to 98% bioavailable relative to the solution; American Thyroid Association task force text: about 70%–80% under optimum fasting conditions1,2,3 |
| Time to peak | ~3 h | No time-to-peak figure appears in the text of the Synthroid or Levoxyl labels; the Synthroid label states that "the peak therapeutic effect of a given dose of SYNTHROID may not be attained for 4 to 6 weeks"1,2 |
| Absorption half-life | 0.5 h (model input) | No absorption half-life figure appears in the text of either label1,2 |
| Time to steady state | About 6 weeks (app's note) | American Thyroid Association task force text: dose adjustments are usually made 4–6 weeks after initiation "based on the half-life of LT4, which reaches steady-state levels by then"; the Synthroid label gives 6 to 8 weeks as the interval for monitoring TSH after any change in dosage in adults with primary hypothyroidism3,1 |
The Synthroid label states that "the majority of the SYNTHROID dose is absorbed from the jejunum and upper ileum".1 It states that "T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans", and that dietary fiber decreases bioavailability.1 The label's drug-interaction tables list phosphate binders (with examples that include calcium carbonate and ferrous sulfate), bile acid sequestrants, ion exchange resins, proton pump inhibitors, sucralfate and antacids as agents that may decrease T4 absorption.1 The same text states that "compared with water, coffee reduced both the maximum concentration (Cmax) and the AUC documented during these absorption studies", and cites a double-isotope study in healthy volunteers with absorption of 64% with food against 80% fasting, a study the authors note did not use participants as their own controls.3 Zamfirescu and Carlson (Thyroid, 2011) gave single doses to eight healthy, euthyroid adults with calcium carbonate, calcium citrate or calcium acetate in doses containing 500 mg elemental calcium and reported that each "significantly reduced levothyroxine absorption by about 20%-25% compared with levothyroxine given alone".4 The authors describe the effect of calcium as "modest compared with some other medications previously studied"; the study was supported by NIH grant M01RR10710 and the authors declared no competing financial interests.4 Each subject received 1 mg of levothyroxine on four occasions at least 3 weeks apart, and the effect of calcium varied between subjects, with none of the calcium preparations decreasing the T4 response area in one subject; the authors name as limitations the use of euthyroid subjects, serum T4 measured for only 6 hours, and a relatively short interval of 3 weeks between study visits.4 In the same passage the authors report that in three other individuals the T4 response area was decreased by 66% (calcium carbonate), 54% (calcium citrate) and 47% (calcium acetate).4 Chon and colleagues (Thyroid, 2018) gave 1000 μg of oral levothyroxine, alone or with 12 oz (355 mL) of 2% cow's milk, to ten healthy euthyroid subjects after an overnight fast with a four-week washout, and reported a lower total T4 area under the curve with milk (67.3 ± 12.1 against 73.5 ± 17.0; p = 0.02).5 That study was supported by NIH K23HD068552 and the authors reported no conflicts of interest.5 Mean peak serum total T4 was also lower with milk (13.0 ± 0.9 against 14.1 ± 0.8 μg/dL; p = 0.04); the authors name as limitations the inclusion of only healthy euthyroid participants and the use of 2% cow's milk only, noting that the results may not be applicable to other types of milk.5
Level over 6 weeks
Level, as a share of the peak after one 100 mg dose
As studied: once daily1.
An illustration from a pharmacokinetic model using a half-life of 168 hours (7 days). It is not a measured level or a suggested dose.
Human studies
The table lists one randomised trial (TRUST), a pair of parallel randomised trials (Casey and colleagues) and one cohort study; two absorption studies in healthy volunteers appear under pharmacokinetics above.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Stott and colleagues, TRUST, New England Journal of Medicine 20176 | Double-blind, randomised, placebo-controlled, parallel-group trial; funded by European Union FP7 and others6 | 737 adults aged 65 years or older with persisting subclinical hypothyroidism; mean age 74.4 years, 53.7% women6 | Levothyroxine starting at 50 μg daily (25 μg for body weight under 50 kg or coronary heart disease) with dose adjustment by TSH, against placebo with mock adjustment; 1 year; median dose 50 μg6 | Change in Hypothyroid Symptoms score 0.2 in both groups (difference 0.0; 95% CI -2.0 to 2.1); Tiredness score difference 0.4 (95% CI -2.1 to 2.9); no beneficial effects of levothyroxine on secondary-outcome measures; no significant excess of serious adverse events prespecified as being of special interest6 |
| Casey and colleagues, NICHD Maternal-Fetal Medicine Units Network, New England Journal of Medicine 20178 | Two parallel randomised, placebo-controlled trials (subclinical hypothyroidism; hypothyroxinemia); funded by NICHD and NINDS8 | 677 pregnant women with subclinical hypothyroidism and 526 with hypothyroxinemia, randomised at a mean of 16.7 and 17.8 weeks of gestation8 | Levothyroxine 100 μg daily (subclinical hypothyroidism) or 50 μg daily (hypothyroxinemia) with monthly adjustment, maximum 200 μg, against placebo; children tested to 5 years8 | Median child IQ 97 against 94 (P=0.71) in the subclinical hypothyroidism trial and 94 against 91 (P=0.30) in the hypothyroxinemia trial; no significant between-group differences in other neurocognitive or pregnancy outcomes or in adverse events8 |
| Mammen and colleagues, Baltimore Longitudinal Study of Aging, Thyroid 201510 | Prospective cohort, not a trial; financial support from the Passano Foundation, the Walton Family Foundation and NIH10 | 1450 ambulatory community volunteers monitored 2003 to 201410 | Exposure to thyroid hormone therapy as taken; TSH and thyroid hormone levels every one to four years10 | Low TSH in 9.6% of participants on thyroid hormone and 0.8% of untreated; new cases 17.7 per 1000 person-years on therapy against 1.5 per 1000 unexposed10 |
Deeper analysis: TRUST (older adults with subclinical hypothyroidism)
Stott and colleagues, for the TRUST Study Group, reported in the New England Journal of Medicine in 2017 a double-blind, randomised, placebo-controlled, parallel-group trial of 737 adults aged at least 65 years with persisting subclinical hypothyroidism.6 Persisting subclinical hypothyroidism was defined as a thyrotropin level of 4.60 to 19.99 mIU per liter with a free thyroxine level within the reference range.6 Of these, 368 patients received levothyroxine with dose adjustment according to the thyrotropin level and 369 received placebo "with mock dose adjustment".6 The two primary outcomes were the change in the Hypothyroid Symptoms score and the Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year, with a minimum clinically important difference of 9 points.6 Mean baseline thyrotropin was 6.40±2.01 mIU per liter; at 1 year it was 5.48 mIU per liter with placebo and 3.63 mIU per liter with levothyroxine, at a median dose of 50 μg.6 The authors "found no differences" in either primary outcome (Hypothyroid Symptoms difference 0.0, 95% CI -2.0 to 2.1; Tiredness difference 0.4, 95% CI -2.1 to 2.9), and "no beneficial effects of levothyroxine were seen on secondary-outcome measures".6 On safety, they report "no significant excess of serious adverse events prespecified as being of special interest"; the PubMed record gives no event counts, discontinuation figures or deaths.6 The authors conclude that "levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism", and the study's population was older adults with this diagnosis.6 The record states the funding as "European Union FP7 and others" and lists an NIH grant (K24 AR051895).6 The ClinicalTrials.gov entry (NCT01660126) lists the lead sponsor as NHS Greater Glasgow and Clyde, with Leiden University Medical Center among the collaborators, and a status of completed.7 The PubMed record carries no author disclosure statement and no limitations section, so the authors' own stated limitations and any author ties to a sponsor are not reported here.6
Deeper analysis: the pregnancy trials (Casey and colleagues)
Casey and colleagues, for the Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network, reported in the New England Journal of Medicine in 2017 two parallel randomised trials, one in women with subclinical hypothyroidism and one in women with hypothyroxinemia, found by screening singleton pregnancies before 20 weeks of gestation.8 Subclinical hypothyroidism was defined as a thyrotropin level of 4.00 mU or more per liter with a normal free T4; 677 such women and 526 with hypothyroxinemia were randomised.8 The original criterion was a thyrotropin level of 3.00 mU or more per liter; after a planned evaluation the cutoff was increased to 4.00 mU per liter.8 Women began 100 μg (subclinical hypothyroidism) or 50 μg (hypothyroxinemia) of levothyroxine or matching placebo daily, with monthly thyroid tests, sham adjustments for placebo and a maximum daily dose of 200 μg.8 The primary outcome was the child's IQ score at 5 years of age (or at 3 years if the 5-year examination was missing) or death at an age of less than 3 years.8 In the subclinical hypothyroidism trial the median IQ score was 97 (95% CI 94 to 99) with levothyroxine and 94 (95% CI 92 to 96) with placebo (P=0.71); in the hypothyroxinemia trial it was 94 (95% CI 91 to 95) and 91 (95% CI 89 to 93) (P=0.30).8 IQ scores were missing for 4% of children in each trial.8 Deaths before 3 years of age (fetal, neonatal or infant) numbered 4 with levothyroxine and 9 with placebo in the subclinical hypothyroidism trial (P = 0.16), and 3 and 6 in the hypothyroxinemia trial (P = 0.34).8 The authors report no significant differences in overall or serious adverse events in either trial, and describe serious adverse events as rare.8 For secondary outcomes, "no adjustments were made for multiple comparisons".8 The authors name a limitation: "the relatively late time during gestation at which women were randomly assigned to the trial groups", with randomisation at a mean of 16.7 and 17.8 weeks.8 They conclude that they "did not find significantly better neurodevelopmental outcomes" in children whose mothers received thyroxine, and that the trials "showed no significant effect of thyroxine treatment on pregnancy and neonatal outcomes".8 Funding came from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the National Institute of Neurological Disorders and Stroke, and the authors state: "No potential conflict of interest relevant to this article was reported".8 The registry entry (NCT00388297) names The George Washington University Biostatistics Center as lead sponsor and lists a status of completed.9
Deeper analysis: Baltimore Longitudinal Study of Aging (Mammen and colleagues)
Mammen and colleagues reported in Thyroid in 2015 a cohort study, not a trial, in which 1450 community volunteers had TSH and thyroid hormone levels and medication use monitored every one to four years between 2003 and 2014.10 The authors report that the vast majority of those on thyroid hormone were using levothyroxine alone, with two participants on desiccated thyroid preparations and one on cytomel as well as levothyroxine.10 The authors defined overtreatment as "a TSH below the lower limit of the reference range".10 At first measurement low TSH was present in 12 of 125 participants on thyroid hormone (9.6%) and 10 of 1318 untreated participants (0.8%), and new cases occurred at 17.7 per 1000 person-years of exposure to therapy (CI 9.5-32.8 in the results text, 9-32 in the summary section) against 1.5 per 1000 person-years unexposed (CI 0.7-2.9); the authors state that the vast majority of new cases were subclinical.10 Among those on thyroid hormone, the authors report new cases at 25.2 per 1000 person-years in women against 4.8 in men.10 The authors report that for one-third of treated participants with follow-up data overtreatment persisted at least two years.10 The outcome measure was low TSH (thyrotoxicosis); the authors cite atrial fibrillation and low bone mineral density as associations with thyrotoxicosis in their background and as a consequent risk of overtreatment in their discussion.10 The authors name a sampling limitation: "annual data were not available for all participants, only for those aged 80 years and older", so their estimates "represent a lower limit".10 The acknowledgments state that financial support came from the Passano Foundation, the Walton Family Foundation, NIH grant K23DK095954 and the NIH Intramural Research Program, National Institute on Aging, and the author disclosure statement reads "No competing financial interests exist".10
Doses reported in studies and on labels
Sources in this part
The app lists a typical dose of 25 to 200 mcg per day by mouth, and its notes state that dosing is set by a prescriber.
| Source and setting | Population | Dose reported |
|---|---|---|
| Synthroid label, adults1 | Adults diagnosed with hypothyroidism | Full replacement dose 1.6 mcg/kg/day, with some patients requiring a lower starting dose; titration by 12.5 to 25 mcg increments every 4 to 6 weeks1 |
| Synthroid label, cardiac risk and older age1 | Adults at risk for atrial fibrillation or with underlying cardiac disease; geriatric patients | A lower starting dose (less than 1.6 mcg/kg/day), with titration every 6 to 8 weeks for the cardiac group1 |
| Synthroid label, upper range1 | Adults | Dosages greater than 200 mcg/day are seldom required; tablets are supplied from 25 mcg to 300 mcg1 |
| Synthroid label, pregnancy1 | Pregnant patients with new-onset hypothyroidism, or with pre-existing primary hypothyroidism and serum TSH above the normal trimester-specific range | New onset: 1.6 mcg/kg/day when TSH is 10 mIU per liter or more and 1.0 mcg/kg/day when it is below 10; pre-existing with TSH above the trimester-specific range: an increase of 12.5 to 25 mcg per day1 |
| American Thyroid Association task force, 20143 | Adults; older adults and coronary artery disease | Full replacement roughly 1.6 μg/kg body weight, lower doses (e.g., 25–50 μg) in milder hypothyroidism, and a low LT4 dose (12.5–25 μg/d) for known coronary artery disease; adjustments of 12.5–25 μg/d3 |
| TRUST trial6 | Adults aged 65 or older with subclinical hypothyroidism | Starting dose 50 μg daily (25 μg for body weight under 50 kg or coronary heart disease), adjusted by TSH; median dose 50 μg at 1 year6 |
| Pregnancy trials, Casey and colleagues8 | Pregnant women with subclinical hypothyroidism or hypothyroxinemia | 100 μg daily (subclinical hypothyroidism) or 50 μg daily (hypothyroxinemia), adjusted monthly to a thyrotropin or free T4 goal, maximum 200 μg8 |
The Synthroid label states a single daily dose on an empty stomach, one-half to one hour before breakfast, and a gap of at least 4 hours before or after drugs known to interfere with absorption.1
Side effects reported
Sources in this part
The Synthroid label states that adverse reactions "are primarily those of hyperthyroidism due to therapeutic overdosage".1 It lists, among others, fatigue, increased appetite, weight loss, heat intolerance, headache, nervousness, insomnia, tremors, palpitations, tachycardia, arrhythmias, diarrhea, hair loss, decreased bone mineral density and menstrual irregularities, and notes that seizures have been reported rarely with the institution of therapy.1 The label states that overtreatment or undertreatment "may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, gastrointestinal function, and glucose and lipid metabolism", and that the drug "has a narrow therapeutic index".1 On the heart, the label states that over-treatment "may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients".1 It adds that "atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly".1 On bone, the label states that "increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women".1 For overdosage, the label states that "cerebral embolism, shock, coma, and death have been reported".1 The Levoxyl label separately lists reports of "choking, gagging, tablet stuck in throat, and dysphagia with LEVOXYL tablets, predominately when LEVOXYL tablets were not taken with water".2 The Synthroid label states that the drug "increases the response to oral anticoagulant therapy", and that in patients with diabetes mellitus it "may worsen glycemic control and result in increased antidiabetic agent or insulin requirements".1 In the Baltimore cohort, the authors write that "virtually the sole risk attributable to therapy is overtreatment resulting in thyrotoxicosis with consequent increased risk for atrial fibrillation and decreased bone density".10
Bloodwork and markers
Sources in this part
The app lists TSH, T4, heart rate and lipids as markers to monitor. The Synthroid label states that in adult patients with primary hypothyroidism serum TSH is monitored 6 to 8 weeks after any change in dosage, and that on a stable dosage clinical and biochemical response is evaluated every 6 to 12 months.1 The American Thyroid Association task force text states that, with the exception of secondary (central) hypothyroidism, rare instances of peripheral thyroid hormone resistance and analytic interference with its measurement, serum TSH is the parameter used to adjust the LT4 dose, with the target TSH "typically being 0.5 to 3.5 or 4 mIU/L", and that the target may vary depending on patient age and underlying comorbidities.3 The label states that biotin supplementation "may interfere with immunoassays for TSH, T4, and T3, resulting in erroneous thyroid hormone test results".1 The label states that "pregnancy may increase SYNTHROID requirements", and the American Thyroid Association task force text lists pregnancy among the changes that raise requirements.1,3
Regulatory and anti-doping status
The DailyMed records cited here include the Synthroid label (initial US approval 2002) and the Levoxyl label (initial US approval 2001), both marked for prescription use.1,2 A text search of the World Anti-Doping Agency 2026 Prohibited List document, whose effective date is 01 January 2026, returned no match for "thyro", so levothyroxine and thyroid hormone are not named in that text.11
Storage and handling
Sources in this part
The Synthroid label states: "Store SYNTHROID at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)".1
What is not known
The Synthroid and Levoxyl label text gives no time-to-peak or absorption half-life, so the app's figures of about 3 hours and 0.5 hours have no label figure beside them here.1,2 The label's absorption range of 40% to 80% is wide, and the American Thyroid Association task force text notes that only one of seven studies of co-administration with foods and beverages in adults was randomised, "thus limiting the ability to draw firm conclusions from the data".1,3 TRUST enrolled adults aged 65 or older with persisting subclinical hypothyroidism (thyrotropin level 4.60 to 19.99 mIU per liter with free thyroxine within the reference range), and the pregnancy trials enrolled women with subclinical hypothyroidism or hypothyroxinemia and excluded women found to have overt hypothyroidism at screening; the Synthroid label's replacement-therapy use covers primary, secondary and tertiary congenital or acquired hypothyroidism.6,8,1 Only US labels are cited here, so European, Australian and other national product information is not summarised here. The PubMed record for TRUST carries no author disclosure statement, event counts or limitations section.6
Frequently asked questions
What is the half-life of levothyroxine?
The Synthroid label lists levothyroxine's half-life as 6 to 7 days in euthyroid patients, with 3 to 4 days in hyperthyroidism and 9 to 10 days in hypothyroidism, and the app lists about 7 days (168 hours).1
Is levothyroxine banned by WADA?
A text search of the 2026 WADA Prohibited List document for "thyro" returned no match, so levothyroxine is not named in that text.11
How much of an oral levothyroxine dose is absorbed?
What does the boxed warning on levothyroxine say?
The Synthroid boxed warning is headed "WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS".1 It states that doses beyond the range of daily hormonal requirements may produce serious or even life-threatening manifestations of toxicity.1 The highlights section adds that larger doses may produce such manifestations, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.1
Did levothyroxine improve symptoms in older adults with subclinical hypothyroidism?
In the TRUST trial of 737 adults aged 65 or older, the Hypothyroid Symptoms score changed by 0.2 in both groups (difference 0.0; 95% CI -2.0 to 2.1) at 1 year.6 The second primary outcome, the Tiredness score, differed by 0.4 (95% CI -2.1 to 2.9), and the authors report that no beneficial effects of levothyroxine were seen on secondary-outcome measures.6 The authors reported no significant excess of serious adverse events prespecified as being of special interest.6
Did levothyroxine in pregnancy change children's IQ?
In the two pregnancy trials by Casey and colleagues, median child IQ was 97 with levothyroxine against 94 with placebo (P=0.71) in subclinical hypothyroidism and 94 against 91 (P=0.30) in hypothyroxinemia.8 The authors name the relatively late randomisation, at a mean of 16.7 and 17.8 weeks of gestation, as a limitation.8
Does levothyroxine interact with warfarin?
The Synthroid label states that the drug "increases the response to oral anticoagulant therapy".1
What reduces levothyroxine absorption?
The Synthroid label lists phosphate binders, bile acid sequestrants, ion exchange resins, proton pump inhibitors, sucralfate and antacids as agents that may decrease T4 absorption.1 In single-dose studies of healthy volunteers, 500 mg of elemental calcium with 1 mg of levothyroxine reduced absorption by about 20%-25% in eight healthy adults, and 12 oz of 2% milk with 1000 μg of levothyroxine lowered total T4 AUC in ten healthy subjects.4,5
How long does levothyroxine take to reach steady state?
The American Thyroid Association task force text states that, based on the half-life of LT4, steady-state levels are reached by 4–6 weeks after initiation, while the app's notes give about 6 weeks.3
Guides, tools and comparisons
References
- AbbVie Inc. Synthroid (levothyroxine sodium) tablets. US prescribing information, DailyMed label version 1537, 2024. DailyMed label (Synthroid)
- Pfizer Laboratories Div Pfizer Inc. Levoxyl (levothyroxine sodium) tablets. US prescribing information, DailyMed label version 13, 2026. DailyMed label (Levoxyl)
- Jonklaas J, et al. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid 2014. PMID 25266247
- Zamfirescu I, Carlson HE. Absorption of Levothyroxine When Coadministered with Various Calcium Formulations. Thyroid 2011. PMID 21595516
- Chon DA, et al. Concurrent Milk Ingestion Decreases Absorption of Levothyroxine. Thyroid 2018. PMID 29589994
- Stott DJ, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med 2017. PMID 28402245
- ClinicalTrials.gov NCT01660126. Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST). Registry entry. NCT01660126
- Casey BM, et al. Treatment of Subclinical Hypothyroidism or Hypothyroxinemia in Pregnancy. N Engl J Med 2017. PMID 28249134
- ClinicalTrials.gov NCT00388297. Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy. Registry entry. NCT00388297
- Mammen JS, et al. Thyroid Hormone Therapy and Risk of Thyrotoxicosis in Community-Resident Older Adults: Findings from the Baltimore Longitudinal Study of Aging. Thyroid 2015. PMID 26177259
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list